Zimmer Biomet Holdings, Inc. (NYSE:ZBH)‘s stock had its “buy” rating restated by equities research analysts at BMO Capital Markets in a research report issued to clients and investors on Tuesday, July 11th. They presently have a $136.00 target price on the medical equipment provider’s stock. BMO Capital Markets’ target price would suggest a potential upside of 15.32% from the company’s current price.
Several other research firms also recently weighed in on ZBH. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Thursday, April 13th. Canaccord Genuity reissued a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Royal Bank Of Canada raised their target price on Zimmer Biomet Holdings from $133.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) assumed coverage on Zimmer Biomet Holdings in a research report on Tuesday, May 16th. They set a “sell” rating and a $92.00 target price for the company. Finally, Wells Fargo & Company lowered Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research report on Friday, April 28th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $137.76.
Zimmer Biomet Holdings (NYSE:ZBH) traded down 0.73% on Tuesday, reaching $117.07. 227,092 shares of the company’s stock were exchanged. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49. The stock has a market capitalization of $23.62 billion, a P/E ratio of 33.34 and a beta of 1.20. The firm’s 50 day moving average is $127.65 and its 200 day moving average is $121.39.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter last year, the business earned $2.02 EPS. Zimmer Biomet Holdings’s revenue was up 1.1% on a year-over-year basis. Analysts expect that Zimmer Biomet Holdings will post $8.24 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) Given “Buy” Rating at BMO Capital Markets” was reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/07/bmo-capital-markets-reiterates-buy-rating-for-zimmer-biomet-holdings-inc-zbh-updated-updated-updated.html.
In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the company. MARSHALL WACE ASIA Ltd acquired a new position in shares of Zimmer Biomet Holdings during the first quarter valued at approximately $38,621,000. Cibc World Markets Corp increased its position in shares of Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock valued at $2,565,000 after buying an additional 7,269 shares in the last quarter. Caxton Associates LP acquired a new position in shares of Zimmer Biomet Holdings during the first quarter valued at approximately $403,000. Thrivent Financial for Lutherans increased its position in shares of Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock valued at $737,000 after buying an additional 450 shares in the last quarter. Finally, Auxier Asset Management increased its position in shares of Zimmer Biomet Holdings by 3.3% in the fourth quarter. Auxier Asset Management now owns 86,514 shares of the medical equipment provider’s stock valued at $8,928,000 after buying an additional 2,750 shares in the last quarter. Institutional investors own 83.62% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.